Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

NCT02820935 ↗

Phase 1 Completed 36 enrolled Celgene Corporation

Non-randomizedCrossoverOpen-labelTreatment

Summary

This is a two-part study to be conducted at a single study site in the US. Both parts of the study may be conducted in parallel. A total of approximately 38 subjects will participate in this study, with approximately 19 subjects in Part 1 and approximately 19 subjects in Part 2. Each subject may only participate in one of the parts.

Timeline

Start: 2016-07
Primary completion: 2016-09
Completion: 2016-09

Publications

Gaudy A, Atsriku C, Ye Y, MacGorman K, Liu L, Xue Y, Surapaneni S, Palmisano M. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects. Eur J Clin Pharmacol. 2021 Feb;77(2):223-231. doi: 10.1007/s00228-020-03004-w. Epub 2020 Sep 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Iberdomide	Small molecule	0.6 mg	—
Subject	Itraconazole	Small molecule	200 mg	—
Subject	Rifampin	Small molecule	600 mg	—

Indications

No indication recorded.